메뉴 건너뛰기




Volumn 11, Issue , 2011, Pages

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; COLLAGEN TYPE 1; FENOFIBRATE; LEPTIN; METHYLCELLULOSE; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; UNCLASSIFIED DRUG; WYETH 14643;

EID: 79957507671     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-11-11     Document Type: Article
Times cited : (66)

References (77)
  • 1
    • 0025132245 scopus 로고
    • Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
    • 10.1038/347645a0, 2129546
    • Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347(6294):645-650. 10.1038/347645a0, 2129546.
    • (1990) Nature , vol.347 , Issue.6294 , pp. 645-650
    • Issemann, I.1    Green, S.2
  • 2
    • 34250213233 scopus 로고    scopus 로고
    • Evolution of peroxisome proliferator-activated receptor agonists
    • 10.1345/aph.1K013, 17519293
    • Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007, 41(6):973-983. 10.1345/aph.1K013, 17519293.
    • (2007) Ann Pharmacother , vol.41 , Issue.6 , pp. 973-983
    • Chang, F.1    Jaber, L.A.2    Berlie, H.D.3    O'Connell, M.B.4
  • 4
    • 0036183630 scopus 로고    scopus 로고
    • The mechanisms of action of PPARs
    • 10.1146/annurev.med.53.082901.104018, 11818483
    • Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435. 10.1146/annurev.med.53.082901.104018, 11818483.
    • (2002) Annu Rev Med , vol.53 , pp. 409-435
    • Berger, J.1    Moller, D.E.2
  • 6
    • 18044376795 scopus 로고    scopus 로고
    • PPARs: therapeutic targets for metabolic disease
    • 10.1016/j.tips.2005.03.003, 15860371
    • Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005, 26(5):244-251. 10.1016/j.tips.2005.03.003, 15860371.
    • (2005) Trends Pharmacol Sci , vol.26 , Issue.5 , pp. 244-251
    • Berger, J.P.1    Akiyama, T.E.2    Meinke, P.T.3
  • 7
    • 0030952937 scopus 로고    scopus 로고
    • Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
    • 10.1073/pnas.94.9.4312, 20719, 9113986
    • Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997, 94(9):4312-4317. 10.1073/pnas.94.9.4312, 20719, 9113986.
    • (1997) Proc Natl Acad Sci USA , vol.94 , Issue.9 , pp. 4312-4317
    • Forman, B.M.1    Chen, J.2    Evans, R.M.3
  • 8
    • 0023202190 scopus 로고
    • Peroxisome proliferation and hepatocarcinogenesis
    • 10.1093/carcin/8.5.631, 3555880
    • Rao MS, Reddy JK. Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 1987, 8(5):631-636. 10.1093/carcin/8.5.631, 3555880.
    • (1987) Carcinogenesis , vol.8 , Issue.5 , pp. 631-636
    • Rao, M.S.1    Reddy, J.K.2
  • 9
    • 54349107126 scopus 로고    scopus 로고
    • The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo
    • Still K, Grabowski P, Mackie I, Perry M, Bishop N. The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo. Calcif Tissue Int 2008,
    • (2008) Calcif Tissue Int
    • Still, K.1    Grabowski, P.2    Mackie, I.3    Perry, M.4    Bishop, N.5
  • 10
    • 0029995670 scopus 로고    scopus 로고
    • Thiazolidinediones in the treatment of insulin resistance and type II diabetes
    • 10.2337/diabetes.45.12.1661, 8922349
    • Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996, 45(12):1661-1669. 10.2337/diabetes.45.12.1661, 8922349.
    • (1996) Diabetes , vol.45 , Issue.12 , pp. 1661-1669
    • Saltiel, A.R.1    Olefsky, J.M.2
  • 11
    • 34249023565 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism
    • 10.1111/j.1472-8206.2007.00486.x, 17521292
    • Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 2007, 21(3):231-244. 10.1111/j.1472-8206.2007.00486.x, 17521292.
    • (2007) Fundam Clin Pharmacol , vol.21 , Issue.3 , pp. 231-244
    • Giaginis, C.1    Tsantili-Kakoulidou, A.2    Theocharis, S.3
  • 12
    • 65549093430 scopus 로고    scopus 로고
    • PPAR-Alpha Agonists Increase Bone Mineral Density in Female Rats
    • Minneapolis, Minnesota, USA
    • Syversen U, Aune G, Thommesen L. PPAR-Alpha Agonists Increase Bone Mineral Density in Female Rats. Abstract at ASBMR 25th Annual Meeting 2003, Minneapolis, Minnesota, USA.
    • (2003) Abstract at ASBMR 25th Annual Meeting
    • Syversen, U.1    Aune, G.2    Thommesen, L.3
  • 13
    • 65549111189 scopus 로고    scopus 로고
    • Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone
    • 10.1186/1472-6823-9-10, 2678137, 19331671
    • Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 2009, 9:10. 10.1186/1472-6823-9-10, 2678137, 19331671.
    • (2009) BMC Endocr Disord , vol.9 , pp. 10
    • Syversen, U.1    Stunes, A.K.2    Gustafsson, B.I.3    Obrant, K.J.4    Nordsletten, L.5    Berge, R.6    Thommesen, L.7    Reseland, J.E.8
  • 14
    • 0036090467 scopus 로고    scopus 로고
    • Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation
    • 10.1210/en.143.6.2376, 12021203
    • Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143(6):2376-2384. 10.1210/en.143.6.2376, 12021203.
    • (2002) Endocrinology , vol.143 , Issue.6 , pp. 2376-2384
    • Lecka-Czernik, B.1    Moerman, E.J.2    Grant, D.F.3    Lehmann, J.M.4    Manolagas, S.C.5    Jilka, R.L.6
  • 15
    • 0033197899 scopus 로고    scopus 로고
    • Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2
    • 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7, 10412038
    • Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999, 74(3):357-371. 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7, 10412038.
    • (1999) J Cell Biochem , vol.74 , Issue.3 , pp. 357-371
    • Lecka-Czernik, B.1    Gubrij, I.2    Moerman, E.J.3    Kajkenova, O.4    Lipschitz, D.A.5    Manolagas, S.C.6    Jilka, R.L.7
  • 16
    • 0041766341 scopus 로고    scopus 로고
    • Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts
    • 10.1016/S0022-2143(03)00058-1, 12878983
    • Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med 2003, 142(1):29-34. 10.1016/S0022-2143(03)00058-1, 12878983.
    • (2003) J Lab Clin Med , vol.142 , Issue.1 , pp. 29-34
    • Khan, E.1    Abu-Amer, Y.2
  • 18
    • 0029847076 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells
    • Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996, 50(5):1087-1094.
    • (1996) Mol Pharmacol , vol.50 , Issue.5 , pp. 1087-1094
    • Gimble, J.M.1    Robinson, C.E.2    Wu, X.3    Kelly, K.A.4    Rodriguez, B.R.5    Kliewer, S.A.6    Lehmann, J.M.7    Morris, D.C.8
  • 20
    • 0033303538 scopus 로고    scopus 로고
    • Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro
    • 10.1210/en.140.11.5060, 10537132
    • Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999, 140(11):5060-5065. 10.1210/en.140.11.5060, 10537132.
    • (1999) Endocrinology , vol.140 , Issue.11 , pp. 5060-5065
    • Okazaki, R.1    Toriumi, M.2    Fukumoto, S.3    Miyamoto, M.4    Fujita, T.5    Tanaka, K.6    Takeuchi, Y.7
  • 21
    • 0034640397 scopus 로고    scopus 로고
    • Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation
    • 10.1074/jbc.275.19.14388, 10799521
    • Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 2000, 275(19):14388-14393. 10.1074/jbc.275.19.14388, 10799521.
    • (2000) J Biol Chem , vol.275 , Issue.19 , pp. 14388-14393
    • Mbalaviele, G.1    Abu-Amer, Y.2    Meng, A.3    Jaiswal, R.4    Beck, S.5    Pittenger, M.F.6    Thiede, M.A.7    Marshak, D.R.8
  • 22
    • 33751503186 scopus 로고    scopus 로고
    • PPAR agonists modulate human osteoclast formation and activity in vitro
    • 10.1016/j.bone.2006.07.029, 17010686
    • Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007, 40(1):149-159. 10.1016/j.bone.2006.07.029, 17010686.
    • (2007) Bone , vol.40 , Issue.1 , pp. 149-159
    • Chan, B.Y.1    Gartland, A.2    Wilson, P.J.3    Buckley, K.A.4    Dillon, J.P.5    Fraser, W.D.6    Gallagher, J.A.7
  • 23
    • 0035957017 scopus 로고    scopus 로고
    • IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1
    • 10.1073/pnas.041493198, 30157, 11226258
    • Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 2001, 98(5):2443-2448. 10.1073/pnas.041493198, 30157, 11226258.
    • (2001) Proc Natl Acad Sci USA , vol.98 , Issue.5 , pp. 2443-2448
    • Bendixen, A.C.1    Shevde, N.K.2    Dienger, K.M.3    Willson, T.M.4    Funk, C.D.5    Pike, J.W.6
  • 24
    • 12344255130 scopus 로고    scopus 로고
    • Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
    • 10.1677/joe.1.05723, 15525588
    • Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004, 183(1):203-216. 10.1677/joe.1.05723, 15525588.
    • (2004) J Endocrinol , vol.183 , Issue.1 , pp. 203-216
    • Soroceanu, M.A.1    Miao, D.2    Bai, X.Y.3    Su, H.4    Goltzman, D.5    Karaplis, A.C.6
  • 25
    • 0347719481 scopus 로고    scopus 로고
    • Bone is a target for the antidiabetic compound rosiglitazone
    • 1855213, 14500573
    • Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145(1):401-406. 1855213, 14500573.
    • (2004) Endocrinology , vol.145 , Issue.1 , pp. 401-406
    • Rzonca, S.O.1    Suva, L.J.2    Gaddy, D.3    Montague, D.C.4    Lecka-Czernik, B.5
  • 26
    • 14244250617 scopus 로고    scopus 로고
    • Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation
    • Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146(3):1226-1235.
    • (2005) Endocrinology , vol.146 , Issue.3 , pp. 1226-1235
    • Ali, A.A.1    Weinstein, R.S.2    Stewart, S.A.3    Parfitt, A.M.4    Manolagas, S.C.5    Jilka, R.L.6
  • 27
    • 11244346967 scopus 로고    scopus 로고
    • Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone)
    • 10.1007/s00223-004-0224-8, 15549648
    • Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004, 75(4):329-337. 10.1007/s00223-004-0224-8, 15549648.
    • (2004) Calcif Tissue Int , vol.75 , Issue.4 , pp. 329-337
    • Sottile, V.1    Seuwen, K.2    Kneissel, M.3
  • 28
    • 34250847265 scopus 로고    scopus 로고
    • Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone
    • 10.1210/en.2006-1587, 2084459, 17332064
    • Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148(6):2669-2680. 10.1210/en.2006-1587, 2084459, 17332064.
    • (2007) Endocrinology , vol.148 , Issue.6 , pp. 2669-2680
    • Lazarenko, O.P.1    Rzonca, S.O.2    Hogue, W.R.3    Swain, F.L.4    Suva, L.J.5    Lecka-Czernik, B.6
  • 29
    • 33748157382 scopus 로고    scopus 로고
    • Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice
    • 10.1016/j.bone.2006.04.008, 16759917
    • Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, Ke HZ, Brown TA. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 2006, 39(4):796-806. 10.1016/j.bone.2006.04.008, 16759917.
    • (2006) Bone , vol.39 , Issue.4 , pp. 796-806
    • Li, M.1    Pan, L.C.2    Simmons, H.A.3    Li, Y.4    Healy, D.R.5    Robinson, B.S.6    Ke, H.Z.7    Brown, T.A.8
  • 31
    • 34249905512 scopus 로고    scopus 로고
    • Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men
    • 10.2337/dc06-2606, 17363747
    • Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007, 30(6):1574-1576. 10.2337/dc06-2606, 17363747.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1574-1576
    • Yaturu, S.1    Bryant, B.2    Jain, S.K.3
  • 33
    • 34147154970 scopus 로고    scopus 로고
    • The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial
    • 10.1210/jc.2006-2646, 17264176
    • Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92(4):1305-1310. 10.1210/jc.2006-2646, 17264176.
    • (2007) J Clin Endocrinol Metab , vol.92 , Issue.4 , pp. 1305-1310
    • Grey, A.1    Bolland, M.2    Gamble, G.3    Wattie, D.4    Horne, A.5    Davidson, J.6    Reid, I.R.7
  • 34
    • 33646889773 scopus 로고    scopus 로고
    • Bone quality--the material and structural basis of bone strength and fragility
    • 10.1056/NEJMra053077, 16723616
    • Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354(21):2250-2261. 10.1056/NEJMra053077, 16723616.
    • (2006) N Engl J Med , vol.354 , Issue.21 , pp. 2250-2261
    • Seeman, E.1    Delmas, P.D.2
  • 35
    • 26944496131 scopus 로고    scopus 로고
    • Long-term prediction of three-dimensional bone architecture in simulations of pre-, peri- and post-menopausal microstructural bone remodeling
    • Muller R. Long-term prediction of three-dimensional bone architecture in simulations of pre-, peri- and post-menopausal microstructural bone remodeling. Osteoporos Int 2005, 16(Suppl 2):S25-35.
    • (2005) Osteoporos Int , vol.16 , Issue.SUPPL. 2
    • Muller, R.1
  • 36
    • 27944449749 scopus 로고    scopus 로고
    • In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography
    • 10.1210/jc.2005-1258, 16189253
    • Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 2005, 90(12):6508-6515. 10.1210/jc.2005-1258, 16189253.
    • (2005) J Clin Endocrinol Metab , vol.90 , Issue.12 , pp. 6508-6515
    • Boutroy, S.1    Bouxsein, M.L.2    Munoz, F.3    Delmas, P.D.4
  • 37
    • 2342504659 scopus 로고    scopus 로고
    • Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome
    • 10.1038/sj.ijo.0802613, 15007394
    • Sedova L, Seda O, Krenova D, Kren V, Kazdova L. Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. Int J Obes Relat Metab Disord 2004, 28(5):719-725. 10.1038/sj.ijo.0802613, 15007394.
    • (2004) Int J Obes Relat Metab Disord , vol.28 , Issue.5 , pp. 719-725
    • Sedova, L.1    Seda, O.2    Krenova, D.3    Kren, V.4    Kazdova, L.5
  • 38
    • 33750454798 scopus 로고    scopus 로고
    • Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats
    • 10.1016/j.lfs.2006.07.018, 16904700
    • Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 2006, 79(23):2209-2216. 10.1016/j.lfs.2006.07.018, 16904700.
    • (2006) Life Sci , vol.79 , Issue.23 , pp. 2209-2216
    • Pathan, A.R.1    Viswanad, B.2    Sonkusare, S.K.3    Ramarao, P.4
  • 39
    • 4744356246 scopus 로고    scopus 로고
    • Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
    • 10.1016/j.bbrc.2004.09.021, 15464987
    • Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004, 324(1):92-97. 10.1016/j.bbrc.2004.09.021, 15464987.
    • (2004) Biochem Biophys Res Commun , vol.324 , Issue.1 , pp. 92-97
    • Lenhard, J.M.1    Croom, D.K.2    Minnick, D.T.3
  • 41
    • 0027417991 scopus 로고
    • Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions
    • 10.1016/8756-3282(93)90245-6, 8334036
    • Odgaard A, Gundersen HJ. Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone 1993, 14(2):173-182. 10.1016/8756-3282(93)90245-6, 8334036.
    • (1993) Bone , vol.14 , Issue.2 , pp. 173-182
    • Odgaard, A.1    Gundersen, H.J.2
  • 42
    • 2942730560 scopus 로고    scopus 로고
    • Quantification of Bone Microarchitecture with the Structure Model Index
    • 10.1080/01495739708936692, 11264794
    • Hildebrand T, Ruegsegger P. Quantification of Bone Microarchitecture with the Structure Model Index. Comput Methods Biomech Biomed Engin 1997, 1(1):15-23. 10.1080/01495739708936692, 11264794.
    • (1997) Comput Methods Biomech Biomed Engin , vol.1 , Issue.1 , pp. 15-23
    • Hildebrand, T.1    Ruegsegger, P.2
  • 43
    • 0028202806 scopus 로고
    • Muscle contraction increases the in vivo structural strength to the same degree in osteopenic and normal rat tibiae
    • Nordsletten L, Kaastad TS, Obrant KJ, Skjeldal S, Kirkeby OJ, Stokke O, Ekeland A. Muscle contraction increases the in vivo structural strength to the same degree in osteopenic and normal rat tibiae. J Bone Miner Res 1994, 9(5):679-685.
    • (1994) J Bone Miner Res , vol.9 , Issue.5 , pp. 679-685
    • Nordsletten, L.1    Kaastad, T.S.2    Obrant, K.J.3    Skjeldal, S.4    Kirkeby, O.J.5    Stokke, O.6    Ekeland, A.7
  • 44
    • 0032696180 scopus 로고    scopus 로고
    • Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae
    • 10.1007/s002239900723, 10541770
    • Dobson KR, Reading L, Haberey M, Marine X, Scutt A. Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int 1999, 65(5):411-413. 10.1007/s002239900723, 10541770.
    • (1999) Calcif Tissue Int , vol.65 , Issue.5 , pp. 411-413
    • Dobson, K.R.1    Reading, L.2    Haberey, M.3    Marine, X.4    Scutt, A.5
  • 46
    • 84934434922 scopus 로고    scopus 로고
    • Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery
    • 10.1007/978-1-59745-104-8_8, 18463814
    • Kharode YP, Sharp MC, Bodine PV. Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Methods Mol Biol 2008, 455:111-124. 10.1007/978-1-59745-104-8_8, 18463814.
    • (2008) Methods Mol Biol , vol.455 , pp. 111-124
    • Kharode, Y.P.1    Sharp, M.C.2    Bodine, P.V.3
  • 47
    • 49749143702 scopus 로고    scopus 로고
    • Pathogenesis of age-related osteoporosis: impaired mechano-responsiveness of bone is not the culprit
    • 10.1371/journal.pone.0002540, 2481275, 18648530
    • Leppanen OV, Sievanen H, Jokihaara J, Pajamaki I, Kannus P, Jarvinen TL. Pathogenesis of age-related osteoporosis: impaired mechano-responsiveness of bone is not the culprit. PLoS One 2008, 3(7):e2540. 10.1371/journal.pone.0002540, 2481275, 18648530.
    • (2008) PLoS One , vol.3 , Issue.7
    • Leppanen, O.V.1    Sievanen, H.2    Jokihaara, J.3    Pajamaki, I.4    Kannus, P.5    Jarvinen, T.L.6
  • 48
    • 20444440328 scopus 로고    scopus 로고
    • Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis
    • Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005, 23(3):323-330.
    • (2005) Clin Exp Rheumatol , vol.23 , Issue.3 , pp. 323-330
    • Okamoto, H.1    Iwamoto, T.2    Kotake, S.3    Momohara, S.4    Yamanaka, H.5    Kamatani, N.6
  • 49
    • 34249075715 scopus 로고    scopus 로고
    • Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease
    • Celinska-Lowenhoff M, Lowenhoff T, Undas A, Gluszko P. Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease. Thromb Haemost 2007, 97(5):868-870.
    • (2007) Thromb Haemost , vol.97 , Issue.5 , pp. 868-870
    • Celinska-Lowenhoff, M.1    Lowenhoff, T.2    Undas, A.3    Gluszko, P.4
  • 50
    • 0034616069 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts
    • 10.1016/S0014-5793(00)01372-7, 10760525
    • Jackson SM, Demer LL. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 2000, 471(1):119-124. 10.1016/S0014-5793(00)01372-7, 10760525.
    • (2000) FEBS Lett , vol.471 , Issue.1 , pp. 119-124
    • Jackson, S.M.1    Demer, L.L.2
  • 51
    • 0036289332 scopus 로고    scopus 로고
    • Microarray Analysis of Gene Expression Changes in Mouse Liver Induced by Peroxisome Proliferator- Activated Receptor [alpha] Agonists
    • 10.1006/bbrc.2001.6319, 11798191
    • Yamazaki K, Kuromitsu J, Tanaka I. Microarray Analysis of Gene Expression Changes in Mouse Liver Induced by Peroxisome Proliferator- Activated Receptor [alpha] Agonists. Biochem Biophys Res Commun 2002, 290(3):1114-1122. 10.1006/bbrc.2001.6319, 11798191.
    • (2002) Biochem Biophys Res Commun , vol.290 , Issue.3 , pp. 1114-1122
    • Yamazaki, K.1    Kuromitsu, J.2    Tanaka, I.3
  • 52
    • 37749034527 scopus 로고    scopus 로고
    • Skeletal consequences of thiazolidinedione therapy
    • 10.1007/s00198-007-0477-y, 17901911
    • Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008, 19(2):129-137. 10.1007/s00198-007-0477-y, 17901911.
    • (2008) Osteoporos Int , vol.19 , Issue.2 , pp. 129-137
    • Grey, A.1
  • 53
    • 42749101870 scopus 로고    scopus 로고
    • Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
    • 1779575, 17259663
    • Schwartz AV. Diabetes, TZDs, and Bone: A Review of the Clinical Evidence. PPAR Res 2006, 2006:24502. 1779575, 17259663.
    • (2006) PPAR Res , vol.2006 , pp. 24502
    • Schwartz, A.V.1
  • 54
    • 77956579687 scopus 로고    scopus 로고
    • Rosiglitazone: what went wrong?
    • 10.1136/bmj.c4848, 20819889
    • Cohen D. Rosiglitazone: what went wrong?. BMJ 2010, 341:c4848. 10.1136/bmj.c4848, 20819889.
    • (2010) BMJ , vol.341
    • Cohen, D.1
  • 55
    • 39649125175 scopus 로고    scopus 로고
    • Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway
    • 10.1016/j.lfs.2007.11.033, 18272184
    • Hung SH, Yeh CH, Huang HT, Wu P, Ho ML, Chen CH, Wang C, Chao D, Wang GJ. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway. Life Sci 2008, 82(11-12):561-569. 10.1016/j.lfs.2007.11.033, 18272184.
    • (2008) Life Sci , vol.82 , Issue.11-12 , pp. 561-569
    • Hung, S.H.1    Yeh, C.H.2    Huang, H.T.3    Wu, P.4    Ho, M.L.5    Chen, C.H.6    Wang, C.7    Chao, D.8    Wang, G.J.9
  • 56
    • 48349130853 scopus 로고    scopus 로고
    • The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations
    • 10.1186/1471-213X-8-71, 2488338, 18625072
    • Hasegawa T, Oizumi K, Yoshiko Y, Tanne K, Maeda N, Aubin JE. The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. BMC Dev Biol 2008, 8:71. 10.1186/1471-213X-8-71, 2488338, 18625072.
    • (2008) BMC Dev Biol , vol.8 , pp. 71
    • Hasegawa, T.1    Oizumi, K.2    Yoshiko, Y.3    Tanne, K.4    Maeda, N.5    Aubin, J.E.6
  • 57
    • 40849112979 scopus 로고    scopus 로고
    • Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression
    • 10.1016/j.bone.2007.11.016, 18242157
    • Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Miyahara T. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone 2008, 42(4):765-774. 10.1016/j.bone.2007.11.016, 18242157.
    • (2008) Bone , vol.42 , Issue.4 , pp. 765-774
    • Hounoki, H.1    Sugiyama, E.2    Mohamed, S.G.3    Shinoda, K.4    Taki, H.5    Abdel-Aziz, H.O.6    Maruyama, M.7    Kobayashi, M.8    Miyahara, T.9
  • 58
    • 36849034568 scopus 로고    scopus 로고
    • PPAR-gamma regulates osteoclastogenesis in mice
    • 10.1038/nm1672, 18059282
    • Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007, 13(12):1496-1503. 10.1038/nm1672, 18059282.
    • (2007) Nat Med , vol.13 , Issue.12 , pp. 1496-1503
    • Wan, Y.1    Chong, L.W.2    Evans, R.M.3
  • 59
    • 33745986412 scopus 로고    scopus 로고
    • Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial
    • 10.1016/j.clinthera.2006.05.012, 16861090
    • Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006, 28(5):679-688. 10.1016/j.clinthera.2006.05.012, 16861090.
    • (2006) Clin Ther , vol.28 , Issue.5 , pp. 679-688
    • Derosa, G.1    Cicero, A.F.2    D'Angelo, A.3    Gaddi, A.4    Ciccarelli, L.5    Piccinni, M.N.6    Salvadeo, S.A.7    Pricolo, F.8    Ferrari, I.9    Gravina, A.10
  • 60
    • 21544466158 scopus 로고    scopus 로고
    • A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    • 10.2337/diacare.28.7.1547, 15983299
    • Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28(7):1547-1554. 10.2337/diacare.28.7.1547, 15983299.
    • (2005) Diabetes Care , vol.28 , Issue.7 , pp. 1547-1554
    • Goldberg, R.B.1    Kendall, D.M.2    Deeg, M.A.3    Buse, J.B.4    Zagar, A.J.5    Pinaire, J.A.6    Tan, M.H.7    Khan, M.A.8    Perez, A.T.9    Jacober, S.J.10
  • 61
    • 0036551421 scopus 로고    scopus 로고
    • A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
    • 10.2337/diacare.25.4.708, 11919129
    • Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002, 25(4):708-711. 10.2337/diacare.25.4.708, 11919129.
    • (2002) Diabetes Care , vol.25 , Issue.4 , pp. 708-711
    • Khan, M.A.1    St Peter, J.V.2    Xue, J.L.3
  • 62
    • 0038607705 scopus 로고    scopus 로고
    • Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts
    • 10.1074/jbc.M211610200, 12704187
    • Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY, Shin CS. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003, 278(26):23270-23277. 10.1074/jbc.M211610200, 12704187.
    • (2003) J Biol Chem , vol.278 , Issue.26 , pp. 23270-23277
    • Jeon, M.J.1    Kim, J.A.2    Kwon, S.H.3    Kim, S.W.4    Park, K.S.5    Park, S.W.6    Kim, S.Y.7    Shin, C.S.8
  • 63
    • 49649118727 scopus 로고    scopus 로고
    • The bone-adipose axis in obesity and weight loss
    • 10.1007/s11695-008-9548-1, 18563500
    • Gomez-Ambrosi J, Rodriguez A, Catalan V, Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg 2008, 18(9):1134-1143. 10.1007/s11695-008-9548-1, 18563500.
    • (2008) Obes Surg , vol.18 , Issue.9 , pp. 1134-1143
    • Gomez-Ambrosi, J.1    Rodriguez, A.2    Catalan, V.3    Fruhbeck, G.4
  • 64
    • 79959700247 scopus 로고    scopus 로고
    • Relationships between fat and bone
    • Reid IR. Relationships between fat and bone. Osteoporos Int 2007,
    • (2007) Osteoporos Int
    • Reid, I.R.1
  • 68
    • 0034918777 scopus 로고    scopus 로고
    • Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization
    • 10.1359/jbmr.2001.16.8.1426, 11499865
    • Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, Gordeladze JO, Drevon CA. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 2001, 16(8):1426-1433. 10.1359/jbmr.2001.16.8.1426, 11499865.
    • (2001) J Bone Miner Res , vol.16 , Issue.8 , pp. 1426-1433
    • Reseland, J.E.1    Syversen, U.2    Bakke, I.3    Qvigstad, G.4    Eide, L.G.5    Hjertner, O.6    Gordeladze, J.O.7    Drevon, C.A.8
  • 69
    • 0036234187 scopus 로고    scopus 로고
    • Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling
    • 10.1002/jcb.10156, 11968022
    • Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002, 85(4):825-836. 10.1002/jcb.10156, 11968022.
    • (2002) J Cell Biochem , vol.85 , Issue.4 , pp. 825-836
    • Gordeladze, J.O.1    Drevon, C.A.2    Syversen, U.3    Reseland, J.E.4
  • 70
    • 2342557919 scopus 로고    scopus 로고
    • The many lives of leptin
    • 10.1016/j.peptides.2004.02.014, 15134858
    • Banks WA. The many lives of leptin. Peptides 2004, 25(3):331-338. 10.1016/j.peptides.2004.02.014, 15134858.
    • (2004) Peptides , vol.25 , Issue.3 , pp. 331-338
    • Banks, W.A.1
  • 71
    • 30044434035 scopus 로고    scopus 로고
    • Intracellular signalling pathways activated by leptin
    • 1383660, 16336196
    • Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006, 393(Pt 1):7-20. 1383660, 16336196.
    • (2006) Biochem J , vol.393 , Issue.PART 1 , pp. 7-20
    • Fruhbeck, G.1
  • 72
    • 26444589701 scopus 로고    scopus 로고
    • A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-alpha in obese Zucker rats
    • Galisteo M, Sanchez M, Vera R, Gonzalez M, Anguera A, Duarte J, Zarzuelo A. A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-alpha in obese Zucker rats. J Nutr 2005, 135(10):2399-2404.
    • (2005) J Nutr , vol.135 , Issue.10 , pp. 2399-2404
    • Galisteo, M.1    Sanchez, M.2    Vera, R.3    Gonzalez, M.4    Anguera, A.5    Duarte, J.6    Zarzuelo, A.7
  • 73
    • 4644226667 scopus 로고    scopus 로고
    • Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity
    • 10.1038/oby.2004.118, 15229336
    • Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004, 12(6):962-971. 10.1038/oby.2004.118, 15229336.
    • (2004) Obes Res , vol.12 , Issue.6 , pp. 962-971
    • Vendrell, J.1    Broch, M.2    Vilarrasa, N.3    Molina, A.4    Gomez, J.M.5    Gutierrez, C.6    Simon, I.7    Soler, J.8    Richart, C.9
  • 74
    • 0034999667 scopus 로고    scopus 로고
    • Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia
    • 10.1210/jc.86.5.1930, 11344187
    • Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86(5):1930-1935. 10.1210/jc.86.5.1930, 11344187.
    • (2001) J Clin Endocrinol Metab , vol.86 , Issue.5 , pp. 1930-1935
    • Weyer, C.1    Funahashi, T.2    Tanaka, S.3    Hotta, K.4    Matsuzawa, Y.5    Pratley, R.E.6    Tataranni, P.A.7
  • 75
    • 36248998354 scopus 로고    scopus 로고
    • The effect of thiazolidinediones on adiponectin serum level: a meta-analysis
    • Riera-Guardia N, Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 2007,
    • (2007) Diabetes Obes Metab
    • Riera-Guardia, N.1    Rothenbacher, D.2
  • 76
    • 33846456211 scopus 로고    scopus 로고
    • Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model
    • 10.1016/j.amjhyper.2006.08.002, 17261469
    • Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z, Grossman E, Shamiss A. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am J Hypertens 2007, 20(2):206-210. 10.1016/j.amjhyper.2006.08.002, 17261469.
    • (2007) Am J Hypertens , vol.20 , Issue.2 , pp. 206-210
    • Sharabi, Y.1    Oron-Herman, M.2    Kamari, Y.3    Avni, I.4    Peleg, E.5    Shabtay, Z.6    Grossman, E.7    Shamiss, A.8
  • 77
    • 29044437122 scopus 로고    scopus 로고
    • Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin
    • 10.1016/j.bbrc.2005.11.143, 16338222
    • Yang G, Li L, Tang Y, Boden G. Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin. Biochem Biophys Res Commun 2006, 339(4):1190-1196. 10.1016/j.bbrc.2005.11.143, 16338222.
    • (2006) Biochem Biophys Res Commun , vol.339 , Issue.4 , pp. 1190-1196
    • Yang, G.1    Li, L.2    Tang, Y.3    Boden, G.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.